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Background: Management of patients with cancer is complex, multi-disciplinary, longitudinal and costly. 
Abandonment of treatment by patients and loss to follow up is a common scenario, especially in resource poor 
countries and severely compromises health outcomes. 
Objective: To assess the commitment to drug treatment protocol of patients with Acquired Immunodeficiency 
Syndrome (AIDS)-Related Kaposi’s Sarcoma at Kenyatta National Hospital, Kenya, over a 10 week period . 
Methods: The study design was prospective, observational, cross-sectional period prevalence study on patients 
infected with human immunodeficiency virus (HIV) with Kaposi’s sarcoma. Patients with histological diagnosis of 
Kaposi’s sarcoma were sequentially enrolled into the study as they attended either the Haematology or Radiotherapy 
clinic or during their admission in the wards. The choice of the treatment protocol was left at the discretion of the 
attending physician. A pretested data collection form was used to collect demographic and clinical information about 
the patients, including treatments prescribed and completion of follow up. 
Results: A total of 74 patients were enrolled into the study, 42 (56.8%) males and 32 (43.2%) females. The age 
ranged between 13 years to 55 years. Their treatment protocols included: Vincristine only, Vincristine plus 
Bleomycin, Vincristine plus Bleomycin plus Doxorubicin, Radiotherapy plus Vincristine and Radiotherapy only. Few of 
the patients were not assigned any antitumor treatment. Antiemetic and other conventional medicines were also 
prescribed when necessary. Fifty four (73%) of the patients abandoned treatment, five (6.8%) died, 15(20.3%) 
continued to attend clinic over the 10 week period.  There was no significant association between sex and outcome 
(p=0.661). 
Discussion: The results of this study demonstrate that abandonment of treatment is a major problem among patients 
on treatment for cancer in Kenyatta National Hospital in Kenya. Abandonment of treatment heavily contributes to 
poor clinical outcome hence complicating the burden of cancer in the country. It is therefore important to develop and 
establish follow-up systems to improve adherence to treatment for the cancer patients at Kenyatta National Hospital. 
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1. Introduction 
Cancer claims millions of lives every year all over the 
world. The cure rates are very low and clinical 
outcomes are uncertain. Despite advanced research and 
improved therapeutics in cancer management in the 
developed world, it is estimated that the number of 
cancer cases and deaths is expected to double world 
wide by 2030 (United States Statistic 1999-2010). 
The news of cancer diagnosis is therefore never 
welcome and discussion about cancer still remains a 
taboo in many societies. This leads to denial, failure to 
accept diagnosis hence poor adherence to treatment. 
Despite much progress in cancer research, the cure for 
many adult cancers has remained elusive unlike in 
paediatrics where much success has been achieved and 
7 out of 10 children with cancer are cured (Smith et al, 
2010). 
Various treatment modalities are currently available for 
the management of cancer. Regardless of the treatment 
modality used, the management process is longitudinal, 
complex and multidisciplinary; involving the patient, 
the family, healthcare provider, the health system and 
the society at large. Cancer therapy is associated with 
complications, drug and radiation toxicities, treatment 
failures and or disease relapse (Mwanda et al, 2005). 
These complications and toxicities may lead to poor 
adherence to treatment .It is therefore critical that 
patients on anti-cancer therapy be followed up 
aggressively. It is during follow up, that the patients 
give feedback to the healthcare provider about the 
progress following initiation of treatment .The health 
care provider in return reviews the patient, evaluates 
disease response to treatment; scores the performance 
status of the patient and advices the patient and/ or 
family accordingly.  
Abandonment (non-completion) of treatment and loss 
to follow up creates a hiatus in the management of the 
cancer patients and has been found to be one of the 
leading contributors to treatment failure in paediatric 
oncology. Studies in paediatric oncology have shown 
that abandonment of treatment and loss to follow up is 
a major contributor to treatment failure in children with 
cancer in developing countries ((Arora et al, 2007; 
Njuguna et al, 2014; Sitaresmi et al, 2010). 
In the developed countries, toxicity related to treatment 
and relapse are the main causes of treatment failure. 
Abandonment of treatment or loss to follow is reduced 
due to intervention from the social services department 
who may take court action against the parent or 
guardian who fail to take their children to hospital. This 
extended support ensures that the patient receives 
treatment as scheduled and when necessary (Arora et 
al, 2007). Such support does not exist in Kenya. The 
level and impact of treatment abandonment is poorly 
documented hence the need for this study. 
Kaposi’s sarcoma (KS) is a tumour caused by human 
herpes virus-8 (HHV8); it was originally described 
by Moritz Kaposi in 1872. It became widely known as 
one of the AIDS defining illnesses in the 1980s. It is a 
systemic disease that presents with cutaneous lesions 
with or without involvement of internal organs. Four 
subtypes have been described: Classic KS, (affecting 
middle aged men of Mediterranean descent); African 
endemic KS, (common in young men within tropical 
Africa); Iatrogenic KS, (found in patients on 
immunosuppressive therapy); and AIDS -related KS. 
The cutaneous lesions in KS are erythematous to 
violaceous with diverse morphologies ranging from 
macular, patchy plaques, nodular to exophytic lesions. 
Cutaneous KS lesions can be solitary and localized while 
the disseminated KS may involve the oral cavity, lymph 
nodes and viscera.  
Classic KS tends to be indolent, presenting with lesions 
on lower extremities. African endemic KS and AIDS-
related KS tend to be more aggressive involving the 
viscera (Chang et al, 1994). 
AIDS-related KS presents with cutaneous lesions that 
begin as one or several red to purple macules, rapidly 
progressing to papules, nodules and plagues, with a 
predilection for the head, trunk, mucous membranes, 
lymph nodes and the viscera. Kaposi’s sarcoma is over 
300 times more common in AIDS patients than in renal 
transplant recipients (Beral et al, 1990). 
Diagnosis of KS is made by tissue biopsy of the lesion. 
Treatment is based on the subtype and the extent of 
disease (localized versus systemic). Localized cutaneous 
disease may be treated with cryotherapy, intralesional 
injections of Vinblastine, Alitretinoin gel, Radiotherapy, 
topical immunotherapy such as Imiquimod, or surgical 
excision. Extensive cutaneous disease and/or visceral 
disease may require intravenous chemotherapy and 
immunotherapy. Discontinuation of treatment or 
reduction of drug dose is recommended when the 
disease is due to immunosuppressive therapy.  
In the management of AIDS-related KS, highly active 
antiretroviral therapy (HAART) has been shown to 
induce disease regression. AIDS-related KS is not 
curable but it can often be effectively palliated for many 
years and this is the aim of treatment. The study set out 
to explore the level of abandonment to treatment and 
its impact on patients with AIDS - related KS attending 
clinic at KNH. 
2. Methodology 
2.1 Study design 
The study design was prospective, observational, cross-
sectional period prevalence on patients infected with 
HIV with KS on follow up at Kenyatta National Hospital. 
2.2 Recruitment of participants  
Male and female patients of any age who were HIV 
positive with histological diagnosis of KS and who were 
on follow up at the Haematology, Radiotherapy Clinics 
and in the Oncology wards of KNH were recruited after 
obtaining their consent. Patients with KS and not 
infected with HIV and those HIV infected who did not 
consent to be enrolled in the study. 
Patients with histological diagnosis of KS were 
sequentially enrolled into the study during clinic 
attendance and during their admission into the 
oncology wards. 
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2.3 Data collection and management 
A pretested data collection form was designed to collect 
and document data including demographic details of the 
patient, past medical history and past hospital 
admissions. The form in addition provided for 
documentation of the treatment prescribed for KS and 
any other treatment that was considered necessary for 
the patient. Results of physical examination, systemic 
enquiry, laboratory findings, anatomic site of lesion and 
the changes observed at the site of lesion during 
treatment were documented. 
2.4 Assignment to treatment 
The attending physician assigned and prescribed the 
treatment protocol to the participants. The protocols 
included either single drug agent Vincristine or multiple 
drug agents such as Vincristine and Bleomycin; 
Vincristine, Doxorubicin and Bleomycin, or Vincristine 
and Radiotherapy and Radiotherapy only. A few 
patients were not prescribed any specific treatment for 
the KS. The choice of the treatment protocol was left at 
the discretion of the attending physician. 
Follow up of the enrolled patients continued over a 
period of 10 weeks from the date of enrolment of each 
patient. 
2.5 Statistical analysis and presentation of data 
The results were analysed using the Instat Biostatistics 
program from the Department of Public Health 
Pharmacology and Toxicology University of Nairobi. 
Quantitative variables were described in medians, 
means and percentages while strength of association 
was tested using Pearson’s Chi square test. Results were 
considered to be significant when P values were less 
than 0.05 (P <0.05). 
 
2.6 Ethical considerations 
The study was carried out between September –
December 2005 after ethical approval by the Kenyatta 
National Hospital (KNH) - University of Nairobi (UoN) 
Ethics and Research Committee (ERC) (Ref: KNH-
ERC/01/3111). The ethics approval number is 
P148/8/2005. 
3.  Results 
Seventy four patients aged between 13 to 55 years were 
enrolled into the study. Of these, 42 (56.7%) were males 
and 32 (43.2%) were females. Fifty four (73%) lived in 
the urban area (within Nairobi City and its suburbs), 
while 20 (27%) lived in the rural areas (Table 1). 
Table 1: Demographic Data of Patients 
 
Groups 
No. of Patients 
(N=74) 
% 
Gender  Male 42 57 
 Female 32 43 
Age Range 11-20 4 5 
 21-30 20 27 
 31-40 30 41 
 41-50 15 20 
 50 and above 5 5 
Residence* Rural 20 27 
Urban 54 73 
* 6 months prior to the first hospital visit 
  Table 2: Specific anti-tumour therapy and the outcome of follow up over 10 weeks 
Treatment 
Outcome of follow-up 
Died 
On therapy > 10 
weeks 
Abandoned 
treatment 
Total No. of 
patients 
None 0 2 5 7 
RT 2 4 6 12 
RT/Vin 0 0 1 1 
Vin 0 2 1 3 
Vin. A 0 0 3 3 
ACT.D 1 0 1 2 
Vin. B 2 7 35 44 
Vin. B.A 0 0 2 2 
Total 5 15 54 74 
 KEY: None – no antitumor therapy was administered, RT - Radiotherapy, Vin – Vincristine; A - Adriamycin;  
 ACT.D - Actinomycin-D; B - Bleomycin 
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 Table 3: Relationship between sex of patient and outcome 
Sex 
Outcome of follow up 
Total 
Admitted to hospital 
Attended clinic 
over 10 weeks 
Abandoned treatment 
within 10 weeks 
Female 2 5 25 32 
Male 3 10 29 42 
Total 5 15 54 74 
 
Fifty four (73%) patients abandoned treatment, 
5(6.8%) died, 15(20.2%) continued attending the clinic 
over the 10 week follow up period (Table 2).  
Of the twelve patients who were on radiotherapy, six 
(50%) abandoned treatment at its initiation while four 
(33%) continued on treatment over the 10 week period.  
Fifty five (74%) of the patients were on chemotherapy 
(with or without accompanying radiotherapy). Of these, 
forty four abandoned treatment while nine continued to 
get treatment over the 10 week period. 
Seven (9%) patients were not on any specific treatment 
for KS, out of whom five were lost to follow up. 
It was not possible to establish the reason for 
abandonment of treatment or the fate of the patients 
after they had abandoned treatment. 
Twenty five (46%) of the fifty four who abandoned 
treatment were females while 29 (54%) were males 
(Table 3). However, there was no significant 
association between sex and outcome of follow up 
(p=0.661)  
4. Discussion 
Abandonment and loss to follow up has been shown to 
contribute to treatment failure in paediatrics (Bonila et 
al 2009, Smith et al 2010). Various factors are thought 
to contribute to abandonment of treatment and loss to 
follow up in cancer patient on treatment, including 
patient-related, treatment-related, healthcare provider-
related and health system-related factors. 
Patient-related factors are interplay between economic 
and psychosocial status of the patient or guardian, and 
which may cause some patients to abandon the 
prescribed treatment and turn to alternative and 
complementary medicine. 
With regard to treatment-related factors, 
chemotherapy, radiotherapy or surgery is associated 
with adverse effects, most of which are not acceptable 
or tolerable to the patient and these may contribute to 
abandonment and loss to follow up. 
Healthcare provider-related factors such as inadequate 
communication between the healthcare provider and 
the patient with regard to diagnosis, treatment, the 
associated toxicities and cost of treatment may lead to 
poor adherence to treatment and poor clinic attendance 
for follow up after treatment is completed (Arora et al, 
2007). 
Health system-related factors refer to the fact that, in 
developing countries like Kenya, cancer management is 
most often administered in a referral facility with 
complex logistical systems which makes it difficult for 
the patient to adhere to treatment.  
The above factors may have contributed to the high 
levels of treatment abandonment found in this study. 
However, statistical association with each factor could 
not be established due to the small patient numbers and 
lack of contact after the abandonment of treatment 
(Arora et al, 2007; Sitaresmi et al, 2009; Njuguna et al, 
2014). 
5. Conclusion 
This study confirms that abandonment of treatment is 
also a common phenomenon among adult cancer 
patients at Kenyatta National Hospital and its impact on 
treatment outcome cannot be ignored. Therefore, it is 
important to develop and establish follow up systems 
for the cancer patients in order to boost adherence to 
treatment and outcome. 
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